JP2014510717A - 小分子ＲＮａｓｅ阻害剤および使用方法 - Google Patents

小分子ＲＮａｓｅ阻害剤および使用方法 Download PDF

Info

Publication number
JP2014510717A
JP2014510717A JP2013551321A JP2013551321A JP2014510717A JP 2014510717 A JP2014510717 A JP 2014510717A JP 2013551321 A JP2013551321 A JP 2013551321A JP 2013551321 A JP2013551321 A JP 2013551321A JP 2014510717 A JP2014510717 A JP 2014510717A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
rnpa
aureus
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013551321A
Other languages
English (en)
Japanese (ja)
Inventor
ポール エム． ダンマン
パトリック ディー． オルソン
ウェイン チルダース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of JP2014510717A publication Critical patent/JP2014510717A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pyrrole Compounds (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
JP2013551321A 2011-01-26 2012-01-26 小分子ＲＮａｓｅ阻害剤および使用方法 Pending JP2014510717A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161436342P 2011-01-26 2011-01-26
US61/436,342 2011-01-26
PCT/US2012/022662 WO2012103295A2 (en) 2011-01-26 2012-01-26 Small molecule rnase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
JP2014510717A true JP2014510717A (ja) 2014-05-01

Family

ID=46581163

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013551321A Pending JP2014510717A (ja) 2011-01-26 2012-01-26 小分子ＲＮａｓｅ阻害剤および使用方法
JP2013551335A Expired - Fee Related JP6010548B2 (ja) 2011-01-26 2012-01-26 小分子ＲＮａｓｅ阻害剤および使用方法
JP2016150928A Expired - Fee Related JP6248151B2 (ja) 2011-01-26 2016-08-01 小分子ＲＮａｓｅ阻害剤および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013551335A Expired - Fee Related JP6010548B2 (ja) 2011-01-26 2012-01-26 小分子ＲＮａｓｅ阻害剤および使用方法
JP2016150928A Expired - Fee Related JP6248151B2 (ja) 2011-01-26 2016-08-01 小分子ＲＮａｓｅ阻害剤および使用方法

Country Status (7)

Country Link
US (4) US9089545B2 (enExample)
EP (3) EP2667872B1 (enExample)
JP (3) JP2014510717A (enExample)
CN (2) CN103635193B (enExample)
AU (2) AU2012211253B2 (enExample)
CA (2) CA2825907C (enExample)
WO (2) WO2012103336A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017538675A (ja) * 2014-10-31 2017-12-28 ユニバーシティー オブ ロチェスター 微生物感染を治療するための相乗的組成物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012211253B2 (en) 2011-01-26 2016-11-10 Board Of Regents Of The University Of Nebraska Small molecule RNase inhibitors and methods of use
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
US10351890B2 (en) 2014-12-09 2019-07-16 Medicosbiotech, Inc. Method for preparing recombinant proteins through reduction of rnpA gene expression
WO2016093606A1 (ko) * 2014-12-09 2016-06-16 한국과학기술원 rnpA 유전자 발현감소를 통한 재조합단백질의 제조방법
EP3697777A1 (en) 2017-10-19 2020-08-26 eFFECTOR Therapeutics, Inc. Benzimidazole-indole inhibitors of mnk1 and mnk2
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
TWI872177B (zh) 2019-12-20 2025-02-11 丹麥商紐韋盧森公司 對核受體具有活性之化合物
JP7713953B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD264918A1 (de) * 1987-11-26 1989-02-15 Paedagogische Hochschule Lisel Verfahren zur herstellung von 1,4-diacyl-thiosemicarbaziden
JPH03182742A (ja) * 1989-12-12 1991-08-08 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US6936432B2 (en) 2000-03-01 2005-08-30 Message Pharmaceuticals Bacterial RNase P proteins and their use in identifying antibacterial compounds
US20020123077A1 (en) 2000-09-29 2002-09-05 O'toole George A. Novel compounds capable of modulating biofilms
US20020052396A1 (en) * 2001-04-23 2002-05-02 Bailey Thomas R. Compounds, compositions and methods for treating or preventing viral infections and associated diseases
US7001924B2 (en) * 2001-09-21 2006-02-21 Message Pharmaceuticals Inhibitors of RNase P proteins as antibacterial compounds
US20050042674A9 (en) 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
WO2003073999A2 (en) * 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pini-modulating compounds and methods of use thereof
GB2386892A (en) * 2002-03-28 2003-10-01 Pantherix Ltd Carboxy containing (phenyl-/heterocyclyl-)methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
US20040176277A1 (en) * 2003-03-03 2004-09-09 Pintex Pharmaceuticals, Inc. Methods of treating Pin1 associated disorders
FR2858324A1 (fr) * 2003-07-30 2005-02-04 Centre Nat Rech Scient Nouveaux composes antibiotiques, compositions pharmaceutiques les contenant et leurs utilisations
WO2005039494A2 (en) * 2003-10-21 2005-05-06 Message Pharmaceuticals, Inc. Inhibitors of rnase p proteins as antibacterial compounds
US7718680B2 (en) * 2004-09-23 2010-05-18 Burnham Institute For Medical Research Inhibition of lethal factor protease activity from anthrax toxin
JP4122049B2 (ja) 2005-09-22 2008-07-23 明治製菓株式会社 メタロ−β−ラクタマーゼ阻害剤
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2727651C (en) * 2008-06-17 2016-04-05 Priscille Brodin Anti-infective compounds
AU2012211253B2 (en) 2011-01-26 2016-11-10 Board Of Regents Of The University Of Nebraska Small molecule RNase inhibitors and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017538675A (ja) * 2014-10-31 2017-12-28 ユニバーシティー オブ ロチェスター 微生物感染を治療するための相乗的組成物

Also Published As

Publication number Publication date
CA2825907A1 (en) 2012-08-02
JP2014511366A (ja) 2014-05-15
US20130303585A1 (en) 2013-11-14
EP2667873A4 (en) 2014-07-30
AU2012211253B2 (en) 2016-11-10
US20150283118A1 (en) 2015-10-08
US9693999B2 (en) 2017-07-04
EP3243513B1 (en) 2019-06-05
EP2667873A1 (en) 2013-12-04
EP3243513A1 (en) 2017-11-15
US20160115124A1 (en) 2016-04-28
US9517230B2 (en) 2016-12-13
US20130296386A1 (en) 2013-11-07
CN103635193A (zh) 2014-03-12
JP6248151B2 (ja) 2017-12-13
WO2012103295A3 (en) 2012-10-11
JP6010548B2 (ja) 2016-10-19
JP2017014246A (ja) 2017-01-19
CN103635191A (zh) 2014-03-12
AU2012211299B2 (en) 2017-02-02
WO2012103336A1 (en) 2012-08-02
CA2825905C (en) 2019-06-04
WO2012103295A2 (en) 2012-08-02
EP2667872B1 (en) 2019-01-02
EP2667872A4 (en) 2014-08-13
CA2825905A1 (en) 2012-08-02
EP2667873B1 (en) 2017-05-31
US9233095B2 (en) 2016-01-12
US9089545B2 (en) 2015-07-28
CN103635193B (zh) 2017-02-08
EP2667872A2 (en) 2013-12-04
AU2012211299A2 (en) 2013-11-14
CA2825907C (en) 2019-07-30

Similar Documents

Publication Publication Date Title
JP6248151B2 (ja) 小分子ＲＮａｓｅ阻害剤および使用方法
US9521845B2 (en) Beta-lactones as antibacterial agents
US9428472B2 (en) Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
AU2012211299A1 (en) Small molecule RNase inhibitors and methods of use
AU2012211253A1 (en) Small molecule RNase inhibitors and methods of use
US9133231B2 (en) Compounds for treating bacterial infections
Basarab et al. Design of inhibitors of Helicobacter pylori glutamate racemase as selective antibacterial agents: incorporation of imidazoles onto a core pyrazolopyrimidinedione scaffold to improve bioavailabilty
US12016874B2 (en) Methods and compositions for treating carbapenem-resistant klebsiella pneumoniae infections
AU2016225942B2 (en) Small molecule RNase inhibitors and methods of use
EP2607361A1 (en) Thiirane and michael acceptor compounds and their medical use